Craft

VIVUS

Stock Price

$0.1

2020-12-14

Market Capitalization

$8.3 M

2020-12-14

Revenue

$69.8 M

FY, 2019

VIVUS Summary

Company Summary

Overview
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs (obesity, sleep, and sexual health). It has developed two products: Qsymia and Stendra. Qsymia is the FDA-approved once-daily prescription weight-loss medicine that contains 2 ingredients that can help you lose weight and keep it off. Vivus has developed an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials. The drug has been approved for use by the FDA, and will be sold under the trademark name Stendra.
Type
Public
Status
Active
Founded
1991
HQ
Campbell, CA, US | view all locations
Website
http://www.vivus.com/
Cybersecurity rating
Sectors

Key People

  • John Amos

    John Amos, Chief Executive Officer

  • Deborah Larsen

    Deborah Larsen, Vice President and Chief Strategy Officer

  • Ted Broman

    Ted Broman, Vice President of Chemistry, Manufacturing and Control

  • Santosh Varghese

    Santosh Varghese, Senior Vice President and Chief Medical Officer

LocationsView all

1 location detected

  • Campbell, CA HQ

    United States

    900 E Hamilton Ave #550

VIVUS Financials

Summary Financials

Revenue (Q1, 2020)
$19.6M
Gross profit (Q1, 2020)
$15.0M
Net income (Q1, 2020)
($5.2M)
Cash (Q1, 2020)
$32.9M
EBIT (Q1, 2020)
($2.0M)
Enterprise value
$216.2M

Footer menu